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WORKSHOP ON CANINE LEISHMANIOSIS TREATMENT AND 
PREVENTION  
 
C. Favrot, Clinical for Small Animal Internal Medicine, Vetsuisse Faculty, University 
of Zurich, Zurich, Switzerland  
 
M. N. Saridomichelakis, Clinic of Medicine, Faculty of Veterinary Medicine, 
University of Thessaly, Karditsa, Greece 
 
Introduction 
Of the 10 species of the genus Leishmania that have been isolated from dogs, 
L. infantum (Syn L. chagasi) is the most important. It has a wide geographical 
distribution, infecting dogs and humans mainly in Mediterranean countries, Portugal, 
West Africa, Southern Asia, Latin America and the USA. In recent years, this parasite 
tends to expand towards northern European countries, probably due to the global 
warming that favors the life cycle of the sandfly vectors. The remaining of this 
presentation will be devoted exclusively to the infection of dogs by L. infantum (Syn 
L. chagasi) and the term canine leishmaniosis (CanL) will refer to the relevant clinical 
disease. 
For the needs of this workshop, the authors have elected to answer some 
important questions regarding the treatment and prevention of CanL as it appears in 
Europe and try to highlight any differences that may exist between endemic and non-
endemic areas.  
 
Should dogs with leishmaniosis be treated or euthanized? Does decision making 
differ depending on whether the dog lives in an endemic or a non-endemic area? 
Are there cases where euthanasia should be considered? (M. Saridomichelakis) 
 Euthanasia has been recommended for serolopositive dogs living in endemic 
areas in order to eliminate the reservoir of the parasite and block the transmission 
cycle. There are three conditions for euthanasia to be effective: a) dogs should be the 
only reservoir of L. infantum. This is not the case, since many other animal species 
can become infected; although their epidemiological role is of low significance, it is 
hard to predict what will happen in the hypothetical scenario that the primary 
reservoir will disappear, b) the percentage of dogs capable to transmit the parasite is 
low, so that their euthanasia is feasible and acceptable from an ethical and social 
point. Although dogs with CanL (2-5% of the canine population) are the most 
infectious, it is known that seropositive dogs (10-30% of the canine population), even 
when asymptomatic, can also transmit the parasite. There is still an open question 
regarding the infectivity of seronegative asymptomatically infected dogs that 
comprise 50-80% of the canine population living in endemic areas; if they are also 
infectious, blocking the transmission cycle using euthanasia would be practically 
equivalent to genocide, c) an effective program of massive screening and elimination 
of reservoirs should be implemented. This is not currently the case, at least in Europe. 
Also, the effectiveness of such a program would be compromised by the large 
numbers of stray dogs present in some endemic areas and, if serolonegative 
asymptomatically infected dogs are sources of infection, by the necessity of expensive 
diagnostic testing (e.g. PCR). These explain the limited effectiveness of programs of 
massive screening and elimination of serologically positive dogs in Latin America. 
An additional argument in favor of euthanasia is that drug-resistant parasites that may 
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be transmitted to humans are avoided. However, this can also be achieved by avoiding 
using the most effective drugs for human visceral leishmaniasis (e.g. amphotericin) in 
the treatment of CanL and by applying insect repellents on all infected dogs. 
Euthanasia has also been proposed for infected dogs living in non-endemic areas in 
an effort to prevent establishment of CanL. Non-endemic areas may be divided into 
those that are free of sandfly vectors and those where such vectors do exist, usually at 
a low density. In the former, introduction of infected dogs does not pose a real danger 
and in the latter the parasite will probably become established in the future and 
autochthonous cases will eventually appear. For all these reasons, this author does not 
favor euthanasia of infected dogs. 
 There are some CanL cases where euthanasia may be considered, including 
those with advanced renal (common) or liver (uncommon) failure. Most of these dogs 
will eventually succumb to the infection, despite antileishmanial and supportive 
treatment. Our usual approach is to emphasize the poor prognosis and, if the owner is 
still willing, to proceed with intensive treatment. Most of these patients die or are 
euthanized within a few weeks because of progressive clinical deterioration. The few 
dogs that may survive usually need lifelong supportive treatment and their organ 
failure will probably deteriorate.  
 
What are the aims of the treatment in canine leishmaniosis? Do they differ 
depending on the clinical picture or between dogs living in endemic or in non-
endemic areas? (M. Saridomichelakis) 
 In theory, the goals of CanL treatment in endemic areas are: a) to control 
the clinical manifestations of the disease, the clinicopathological abnormalities (e.g. 
anemia) and the CanL-associated organ pathology (e.g. renal lesions): although 
clinical cure and amelioration of most laboratory abnormalities is usually achievable, 
the evolution of some pathologic changes, such as glomerulonephritis, is 
unpredictable and they may improve, remain stable or even deteriorate, b) to prevent 
the recurrence of CanL due to either relapse or re-infection, c) to minimize the 
infectivity of treated dogs to sandfly vectors, d) to avoid the induction of drug-
resistant strains of the parasite, and e) to treat any concurrent diseases. In order to 
achieve the first four goals, the aim of CanL treatment would be to completely 
eliminate the parasite and/or to change the immune response of the host. In theory, 
complete elimination of the parasite (parasitological cure) would control CanL-
associated clinical signs and laboratory abnormalities, and would prevent recurrences, 
transmission to sandflies and induction of drug-resistant strains. However, it is now 
well known that this is rarely feasible, perhaps because parasitized cells are present in 
organs and tissues where therapeutic drug concentrations are not achieved and 
because the immune system of susceptible dogs is unable to completely eliminate the 
organism. Also, in the endemic areas it would be meaningless to focus on a target like 
this disregarding the immune status of the dog: even a parasitologically cured dog 
would probably become re-infected during the next transmission season and would 
develop CanL if its immune system was still unable to control unrestricted parasite 
multiplication. For these reasons, treatment of CanL should focus on the reduction of 
parasitic burden along with the induction of protective immune responses against L. 
infantum.  
 Regarding the clinically normal, serologically positive or negative, infected 
dogs that live in endemic areas, the goals of any medical intervention would be 
slightly different: instead of controlling and preventing the recurrence of CanL-
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associated clinical signs, laboratory abnormalities and organ pathology, avoiding their 
appearance should be the goal of any medical intervention. Also, the reduction of 
infectivity to sandfly vectors, although important for serologically positive 
asymptomatic dogs, it may or may not be an issue for their serologically negative 
counterparts. Most serologically negative and many of the serologically positive 
asymptomatically infected dogs (especially those with low antibody titers, negative 
lymph node and bone marrow cytology and positive leishmanin skin test) have 
already effective Leishmania-specific immune responses; for these dogs the 
avoidance of possible insults to their immune system (e.g. continuous exposure to 
sandfly bites, concurrent diseases, immunosuppressive treatment) is of paramount 
importance. On the contrary, for those dogs that are asymptomatic simply because 
they are in the incubation period of CanL, treatment should aim to the induction of 
protective immune responses, similar to the symptomatic dogs. 
 Finally, for symptomatic and asymptomatically infected dogs that live in non-
endemic areas the only difference regarding the objectives of treatment is that re-
infections and infectivity to sandflies are not a consideration. 
 
Should we treat a (healthy, serologically negative) Leishmania-PCR positive dog? 
(C. Favrot) 
PCR is a very sensitive test and some assays may be able to amplify the DNA 
of only one organism within one hundred cells. Regarding CanL, a positive PCR 
means that the dog has been infected with leishmania and still harbors some 
organisms. Some studies have shown that almost all dogs leaving in some endemic 
areas are PCR positive although most of them were healthy and negative in serology. 
In other words, infected does not mean ill. The fate of the disease will depend on the 
immune status of the dog. A healthy, serologically negative but PCR positive dog 
does not need any treatment. It is however wise to monitor the evolution of the 
disease carefully. A serology and protein profile every year may be regarded as a 
sufficient monitoring for such dogs. In case of lymphadenopathy however, lymph 
node cytology should be performed 
 
Is a (healthy, serologically negative) Leishmania-PCR positive dog dangerous for 
other dogs/humans? (C. Favrot) 
The high sensitivity of PCR assay allows the detection of individuals infected 
by very few organisms. The skin of PCR positive dogs is generally infected but in 
most cases with very few organisms. 
Additionally, direct contamination infected dog-other dog or human being is 
probably very rare or, at least, not epidemiologically significant, (Except vertical 
contamination and may be, via bite). Sandflies are necessary for all almost 
contaminations. It is however not proven yet that leishmania-permissive sandflies do 
exist in Northern Europe (the contrary is however not proven). It does mean that 
leishmania-permissive sandflies must be contaminated by the PCR positive dog 
(which is very unlikely because of the very low amount of organism in the skin/ blood 
of the PCR positive dogs) and that these sandflies have a blood meal on other dogs or 
humans. 
This contamination is consequently very unlikely. 
One must however keep in mind that a healthy, serologically negative, PCR 
positive dog is healthy and serologically negative because its immune system prevent 
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any leishmania growth. The immune status of this dog may change and leishmania 
may subsequently begin to grow. 
As well, sandflies seems to develop in Northern Europe and one cannot 
exclude the presence of leishmania-permissive sandflies in this part of Europe. 
It is worth noticing that the best test for infectivity of infected animal is the so-
called xenodiagnosis: laboratory sandflies are fed on the infected dog and 
subsequently tested for leishmania promastigotes. This test is however not available 
for routine analysis and is time consuming. 
 
Is it positive to predict if a healthy Leishmania-PCR positive dog will develop the 
disease? (C. Favrot) 
Unfortunately, it is not possible to predict the development of the disease in 
leishmania-infected healthy individuals. This development depends on the immune 
status of the dogs and this immune status may vary. Healthy infected individuals get a 
protective cellular immune response. Repetitive exposure to leishmania, concurrent 
infectious diseases, hormone imbalances, tumors may impair this response and lead to 
a less protective answer. It is consequently mandatory to monitor the evolution of the 
infection. Serology, protein profile and lymph node cytology are adequate for such 
monitoring. 
It should be emphasized that repetitive exposures to leishmania dramatically 
increase the risk to develop the disease. Infected dogs should consequently be 
protected adequately against further sanflies bites in endemic areas. 
 
 
What are the characteristics of an ideal drug for the treatment of canine 
leishmaniosis? Does this drug exist? (M. Saridomichelakis) 
 The ideal drug for the treatment of CanL should: a) be effective in 
accomplishing the goals (amelioration of clinical signs, clinicopathological 
abnormalities and organ pathology or prevention of their appearance; prevention of 
relapses; elimination of infectivity to sandflies; no induction of drug-resistant strains 
of the parasite) and aims (induction of protective immune responses; reduction or 
elimination of parasitic burden) of the treatment in most, or even all, treated dogs, b) 
be administered orally (this is of particular importance because it dictates whether 
dogs with CanL can be treated by their owners at home or if they need hospitalization 
that will greatly increase the cost of the treatment; for this reason this author prefers to 
classify the available drugs into those that are administered orally and those that 
necessitate parenteral administration), c) be safe, d) be reasonably priced, e) be 
registered for the treatment of CanL, and f) not be used as a first-line or rescue drug 
for the treatment of human visceral leishmaniasis in the same area.  
 Besides many advances in the medical management of CanL, including 
refinement of dosing regimens (e.g. for pentavalent antimonials) and availability of 
new molecules (i.e. miltefosine), it is this author’s opinion that the ideal drug for the 
treatment of CanL does not currently exist. For this reason combination treatment 
(e.g. allopurinol and miltefosine, allopurinol and pentavalent antimonials) is usually 
employed; the addition of allopurinol (that is administered orally, is generally safe 
and very cheap) in the chemotherapeutic protocol will increase its effectiveness, 




What drugs can be used in the treatment of canine leishmaniosis and what’s 
their mode of action? (M. Saridomichelakis) 
 The orally administered drugs include miltefosine, allopurinol, azoles, 
fluoroquinolones, and metronidazole. Miltefosine leads to apoptosis-like cell death. It 
accumulates into macrophages, interacts with amastigote signal transduction 
pathways and inhibits phospholipid, sterol and plasma membrane synthesis. 
Allopurinol is converted to allopurinol riboside and then to 4- 
aminopyrazolopyrimidine, a toxic analogue of ATP, ADP and AMP that blocks RNA 
and protein synthesis. Azoles (e.g. ketoconazole) inhibit cytochrome P450-mediated 
ergosterol synthesis thus leading to alteration of cell membrane fluidity and 
permeability. Fluoroquinolones (enrofloxacin, marbofloxacin) may bind to 
topoisomerase (DNA gyrase) and inhibit DNA synthesis (similar mode of action 
against Leishmania and bacteria). Metronidazole interacts with protozoal DNA 
damaging its helical structure and causing strand breakage (similar mode of action 
against Leishmania and bacteria). 
 The injectable drugs include pentavalent antimonials, aminosidine, 
amphotericin B, and pentamidine. The active molecule of pentavalent antimonials 
(meglumine antimonate, sodium stibogluconate) is actually the trivalent antimony that 
is produced by the reduction of pentavalent antimony in the macrophage (this explains 
why there drugs are far more effective for intracellular than for extracellular parasites) 
and subsequently taken by the amastigotes. The exact biochemical mechanisms that 
lead to amastigote apoptosis are still a matter of debate: they may include inhibition of 
ATP and GTP synthesis, disruption of glucose and fatty acid metabolism through 
structural and functional alternations of glucosomes, and inhibition of key enzymes 
(e.g. phosphofructokinase, pyruvic dehydrogenase). Aminosidine (paromomycin) 
achieves high intracellular concentrations in amastigotes, where it binds to 30S 
ribosomal subunit and interrupts normal protein synthesis (similar mode of action 
against Leishmania and bacteria). Amphotericin B induces apoptosis after 
irreversible binding to amastigote cell membrane ergosterol; it creates pores that alter 
membrane permeability and disrupt the ion gradient and osmotic balance of the 
parasite (similar mode of action against Leishmania and fungal organisms; similar 
mode of anti-Leishmania action with azoles). Also, at least in humans, amphotericin 
B activates macrophages and augments their oxidative burst through the production of 
TNF-a and IL-1. Pentamidine mainly damages parasitic DNA although some 
additional modes of action (inhibition of specific metabolic pathways, direct 
mitochondrial damage) have been proposed.  
 
Does it make sense to use terms like leishmanicide/leishmaniostatic? (C. Favrot) 
The term leishmanicide is probably misleading as it suggests that such 
treatment may be associated with a parasitical cure, which is often not the case. It is 
very important to explain the owners that leishmania-infected dogs will remain 
infected and that the goal of the treatment is to control leishamnia growth and the 
consequence of the disease. The ability of one specific drug to kill the organism 
leishmania (leishmanicide) in comparison with other drugs that only prevent further 
growth (leishmaniostatic) does not mean that all organisms in the infected dog will be 
killed (same situation as for staphylococci for example). It may however mean that 
the number of living organisms within the host will be reduced more quickly and that 
the clinical improvement will be marked. The main goal of the therapy is to reduce 
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the parasite burden in order to positively contribute to the restoration of the 
macrophage ability to kill the parasites. 
 
Is miltefosine the best available treatment for canine leishmaniosis? (C. Favrot) 
It is probably too early to answer this question thoroughly. The first clinical 
studies are encouraging but the clinical experience of the some practioners may be 
slightly different. In comparison with glucatime, miltefsosine presents some 
advantages like the lack of kidney side–effects (even if the nephrotoxicity of 
glaucantime appears limited) and the way of administration. When compared to 
allopurinol, one should mention that miltefosine is presented as leishmanicide 
(allopurinol is leishmaniostatic):see above for comments on this aspect. Studies 
directly comparing the effeicacy of allopurinol and miltefosine in monotherapy have 
not been made but are needed. 
One should however confirm the long-term efficacy and tolerance of the drug 
 
Is it reasonable to treat with allopurinol only? (C. Favrot) 
Most clinician who had used allopurinol in monotherapy reported dramatic 
clinical improvement and maintenance of this improvement during therapy, at least in 
non-endemic areas. One controlled-study also confirms this efficacy in endemic areas. 
On the other hand, it is also obvious that some allourinol-treated leishmanosis dogs do 
not respond anymore after several years of treatment, suggesting that leishmania may 
become allopurinol-resistant. However allopurinol-resistance has only been proven in 
vitro but was never firmly demonstrated in vivo. Other possible explanations for this 
loss of efficacy could be the lack of compliance or concurrent diseases. The potential 
development of allopurinol-resistant strains in endemic areas can be regarded as a 
major concern. On the contrary, in non endemic areas, such resistant strains have 
virtually no chance to develop. 
As resistances seem to develop after several months to years of continuous 
therapy, an option would be to discontinue the treatment after initial improvement and 
to treat recurrence. This option should only be considered after several negative re-
checks assessing that serology titers are low, globulinemia in normal ranges and 
proteinuria and lymph nodes cytology negative. This option requires however a 
subsequent careful monitoring. It is also worth noticing that no study has 
demonstrated the benefit of such an approach. 
Another option would be to use an allopurinol pulse-therapy (one week per 
month). This approach has been documented in a field study. 
It is worth noticing that LeishVet- a group of experts- supports life-long daily 
treatment to prevent relapses. 
 
Why resistance to antileishmanial medication may develop? How we can prove 
it? What can we do to avoid or delay it? (M. Saridomichelakis) 
 The same cellular and subcellular mechanisms that underline bacterial 
resistance may result in Leishmania-resistance to every medication we may use. Apart 
from innate resistance, mechanisms of acquired resistance include: a) reduced 
penetration of the medication into the infection site. This may be one of the reasons 
why parasitological cure is rarely if ever achieved, since most of the drugs do not 
achieve therapeutic concentrations in organs and tissues such as intraocular structures 
and central nervous system, b) amastigote efflux pumps that expel the agents. For 
example, one mechanism of resistance to pentavalent antimonials is the induction of P 
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glucoprotein that results in 2-5 times lower intracellular concentrations of the drug, c) 
inactivation of the drug (e.g. mutation or dowregulation of the enzyme ACR2-
Pentostam reducatase that normally reduces pentavalent antimony to its trivalent 
counterpart), and d) modifications of the target of the drug. For a dog with CanL 
resistance to antileishmanial medication may be present from the beginning (i.e. the 
dog has been infected by an already resistant strain) or it may develop during the 
course of the treatment. 
 Some laboratory methods for the in vitro evaluation of Leishmania 
susceptibility to various chemotherapeutic agents have been developed. However, 
they are not usually available to the practitioner and the correlation between their 
results and treatment outcome has not been extensively evaluated. Resistance is 
clinically suspected: a) when the goals of the treatment are not achieved after an 
adequate time period. For example, it is known that the combination of meglumine 
antimonate (for a month) and allopurinol (on a long-term basis and sometimes for 
life) should result in dramatic clinical and clinocopathological improvement within 
15-30 days, whereas the relevant figures for pentavalent antimonial monotherapy, for 
allopurinol and for metronidazole-spiramycin are 30-60 days, 30-180 days, and 15-45 
days, respectively, b) when some parameters deteriorate (e.g. re-appearance of clinical 
signs and/or laboratory abnormalities, increased antibody titers, increased lymph node 
parasitic density etc) despite ongoing treatment. This is of particular importance in the 
case of allopurinol that is the only medication given on a long-term basis, due to its 
oral administration, safety and low cost. However, it is emphasized that true 
resistance can only be confirmed in vitro and before attributing a treatment failure to 
resistant strains the numerous alternative explanations for a poor therapeutic outcome 
should be excluded (e.g. low doses, infrequent administration, short duration of the 
treatment, permanent pathologic changes, concurrent diseases etc).   
 The two most important factors that contribute to resistance are the exposure 
of the parasite to low drug concentrations for a short period and the repeated 
administration of the same medication. Therefore, to delay development of resistant 
strains, it is recommended to avoid underdosing at any cost and, in case of relapse, not 
to use many times the same “leishmanicidal” medication to the same patient (e.g. this 
author does not use miltefosine or pentavalent antimonials for more than two “cycles” 
of treatment of one-month each in relapsing patients). 
 
How should I monitor the treatment? (C. Favrot) 
Treatments with effective anti-leishmania drugs are usually associated with 
rapid improvement of the clinical signs. It is however currently not know if and when 
treatment should be discontinued. It is well know that serology titers are not strictly 
connected to the severity of the illness but rather linked to the strength of the humoral 
response, which is known to be non-protective. Titers however usually decline during 
successful therapy.   
A reasonable option for monitoring disease development will be to follow 
serology titer, globulinemia and proteinuria as globulinemia is a very sensitive marker 
of the disease and the latter an important prognostic factor. Lymph nodes cytology 
should also be performed, especially in case of lymphadenopathy. 
 
Is the treatment of canine leishmaniosis lifelong or we could discontinue it at 
some time? (M. Saridomichelakis) 
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 In principle, treatment of dogs with CanL that live in endemic areas can be 
discontinued after parasitological cure provided that highly effective preventative 
measures will be instituted to avoid re-infections, whereas parasitological cure is only 
needed for dogs residing in non-endemic areas. Unfortunately, complete eradication 
of parasites is hardly, if ever, achieved and available preventative measures are not 
100% effective. Therefore, we have to rely on the restoration of Leishmania-specific 
immune responses of the host to avoid relapses after treatment discontinuation. 
 Because of lack of strong scientific evidence, the following recommendations 
are mainly based on anecdotal information, experts’ opinions and personal clinical 
experience. Treatment of CanL cannot be stopped before at least one year of 
continuous allopurinol administration, along with a “leishmanicidal” medication (e.g. 
miltefosine, meglumine antimonate) for the first month; the latter may be 
administered for a second one-month period (e.g. at the sixth month) if clinical and 
laboratory abnormalities are still present. Afterwards the dog should be re-examined, 
usually every six months, and every time the minimum data base should include a 
thorough physical examination, hematology, serum biochemistry (with or without 
protein electrophoresis), serology and lymph node cytology. When, at some time 
point, the dog is clinically normal, laboratory results are within normal limits, 
antibody titers markedly decreased (although they do not always become negative) 
and lymph node cytology is negative (at least 100 oil immersion fields should be 
carefully examined) a decision can be made to either discontinue treatment or to 
proceed with secondary prophylaxis (e.g. periodic administration of allopurinol for 
one week per month)-this author usually prefers the latter. In every case, the dog 
should be carefully monitored and the aforementioned examinations should be 
repeated, ideally every 6 months, for the remaining of its life. Every single indication 
of imminent relapse (i.e. reappearance of mild clinical signs, anemia, 
hyperglobulinemia or proteinuria, increased antibody titer, increased lymph node 
parasitic density) should prompt treatment re-institution. 
 Ancillary tests that may or may not be practical, depending on the particular 
setting, and may be helpful in the decision making process include: a) bone marrow 
cytology. Besides invasive sampling, the smear quality is usually superior than in 
lymph node cytology, b) quantitative PCR (real-time PCR) preferably in bone marrow 
samples. It gives more accurate information on the parasitic density (and thus 
indirectly for the parasiticidal activity of the medication and the effectiveness of 
Leishmania-specific cellular immunity of the dog) compared to cytology. In the past, 
negative bone marrow PCR on two occasions separated by 6 months had been 
proposed as a criterion of parasitological cure and treatment discontinuation. 
Currently, with the advances in PCR methodology, a negative result is a rarity; 
furthermore, a negative result does not guarantee the absence of viable parasites in 
other body tissues, c) leishmanin skin test. It examines the delayed-type 
hypersensitivity after intdradermal injection of Leishmania antigen and is usually 
positive in resistant dogs (where treatment may be discontinued) and negative in the 
susceptible ones. 
 
How we define the recurrences of treated dogs? What should we do in case of a 
relapse? (M. Saridomichelakis) 
 Strictly speaking, recurrence of CanL is the re-appearance of the clinical signs 
at some time point after seemingly effective treatment. However, in a broader sense, 
recurrence may also include the re-appearance of clinically important laboratory 
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abnormalities that indicate organ pathology (e.g. anemia, proteinuria) even without 
associated clinical manifestations. These recurrences are usually preceded by an 
increase of Leishmania-specific antibody titers, increase of serum globulins, 
alternations of proteinogram and increased parasitic density (e.g. upon lymph node 
cytology). 
 Clinician’s action in the case of recurrence depends on whether the dog was or 
was not on maintenance treatment (i.e. continuous administration of allopurinol) or 
secondary prophylaxis (i.e. period administration of allopurinol). When the recurrence 
occurs a few months or even years after discontinuation of the medication, which is a 
very common scenario, allopurinol, either alone (mild or no clinical signs, mild 
laboratory abnormalities) or in combination with a “leishmanicidal” drug, should be 
re-instituted. When it occurs in a dog on secondary prophylaxis, continuous 
allopurinol administration with or without a “leishmanicidal” drug should be 
considered. Finally, recurrences of dogs already on continuous allopurinol treatment 
should be treated with the addition of a “leishmanicidal” drug. In every case it is 
emphasized to avoid the repeated use of the same “leishmanicidal” medication in 
order to avoid the induction of resistant strains. Also, it is highly important to 
thorough investigate all these dogs for concurrent diseases that may alter their 
immune responses and render them susceptible to CanL. 
 
Are glucocorticoids contraindicated in dogs with leishmaniosis? (M. 
Saridomichelakis) 
 Systemic glucocorticoids at anti-inflammatory or even immunosuppressive 
doses are frequently needed to control some clinical manifestations of CanL, such as 
uveitis, polyarthritis and epistaxis. Also, their short-term (e.g. for three weeks) 
addition to the treatment regiment has been associated with faster resolution of 
clinical signs, improvement of thrombocytopathy and normalization of 
albumin/globulin ratio. Finally, systemic glucocorticoids are occasionally needed to 
treat concurrent diseases or conditions such as pemphigus folliaceus, immune-
mediated hemolytic anemia and immune-mediated thrombocytopenia. Topical 
glucocorticoids may be needed for the treatment of CanL-associated keratitis and 
anterior uveitis. 
 The disadvantages of systemic glucocorticoid administration, especially at 
high doses, include: a) their effects on the immune system that may downregulate 
Leishmania-specific immune responses through various mechanisms (e.g. reduced 
lymphocyte counts, increased expression of mannose receptors on macrophages, 
upregulation of Th2-like cytokines), b) enhanced parasite survival through increased 
serum iron concentration, increased transferin saturation and decreased serum cooper 
concentration, and c) deterioration of pre-existing renal failure. 
 For these reasons, this author uses systemic glucocorticoids only when needed 
(usually in cases with epistaxis, uveitis and concurrent immune-mediated diseases) 
and at the minimum effective dose and duration of administration. 
 
How can we define a case of autochthonous canine leishmaniosis? Do these cases 
exist in Germany/northern Europe? (M. Saridomichelakis) 
 An autochthonous case means that the dog has become infected by L. infantum 
in the area of its residency. It is important to realize than a small number of 
autochthonous cases does not necessarily mean that the area has become endemic. 
Endemic foci of CanL may be divided into the stable and the unstable ones: stable 
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endemic foci are characterized by continuous dog-to-dog transmission through 
sandfly bites and hence by the appearance of new cases on a yearly basis, whereas in 
unstable foci indisputable autochthonous cases are seen only sporadically and in low 
numbers. However, a few sporadic cases may also occur after infected dogs are 
introduced in a non-endemic area because of non-sandfly mediated transmission of 
the parasite (e.g. using alternative vectors such as ticks, mosquitoes and fleas; after 
direct or vertical transmission, through blood transfusion and after implantation of 
infected transmissible venereal tumor cells). Therefore, areas with sporadic 
autochthonous cases may represent either unstable foci of CanL or non-endemic foci 
where the parasite is transmitted through alternative modes. 
 
Do cases of autochthonous canine leishmaniosis exist in Germany/northern 
Europe? (C. Favrot) 
Several well (and less well-) documented cases suggest that autochtonous 
cases do exist in Switzerland and Germany. Affected regions are mainly Tessin and 
Geneva (Rhone valley) in Switzerland and Bade-Würtemberg (the author has 
observed two well-documented cases in dogs born and always living near Freiburg in 
Brisgau) and Bavaria in Germany. The explanation for that could be a) non sandfly-
mediated transmission b) transmission by sandflies living in northern Europe and not 
identified yet as leishmania-permissive c) the extension to the north of the living area 
of traditional vectors such as phlebotomus perniciosus. Explanation c) is the more 
logical for Tessin and Geneva cases but is very unlikely for cases observed in 
Germany. For those cases, the more logical explanation would be the presence of 
autochtonous yet unidentified permissive vectors infected by untreated dogs living 
permanently in this area. This point emphasizes the importance not only of treating 
clinical cases of CanL but also to monitor carefully leishmania-infected healthy 
individuals. 
 
Are protective treatments protective enough? (C. Favrot) 
Most studies addressing this question led to similar conclusions: Protective 
treatments are associated with a protection rate ranging for 80 to 90%. Most of these 
studies were however carried out in drastic conditions (heavily infected areas, dogs 
living outdoor in groups etc…). It can consequently be anticipated that these 
treatments are very effective for pet dogs. Repetitive exposure to infected sandflies 
bites is known to increase the risk of developing the disease. In this regard, even a non 
perfect protection should be considered useful. It must however be kept in mind that 
these treatment alone should not be regarded as fully protective and that some other 
precautions should be taken. 
 
What should I explain to an owner who wants to go to southern Europe with 
his/her dog? (C. Favrot) 
a. Use protective treatment 
b. Apply them at least several days before the trip 
c. Renew this treatment if necessary 
d. Do not walk the dog during the activity period of the sandflies ( end of the 
afternoon, beginning of the night) 
e. Avoid places where sandflies usually develop (lakes, ponds, bushes etc…) 
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f. Preventive examination 6 months after returning in non-endemic area. For such a  
preventive examination serology and lymph node cytology should be performed 
and globulinemia and proteinuria measured. 
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